# GAPVAC Phase I Trial in Newly Diagnosed Glioblastoma Patients

> **NCT02149225** · PHASE1 · COMPLETED · sponsor: **Immatics Biotechnologies GmbH** · enrollment: 16 (actual)

## Conditions studied

- Glioblastoma

## Interventions

- **DRUG:** APVAC1 vaccine plus Poly-ICLC and GM-CSF
- **DRUG:** APVAC2 vaccine plus Poly-ICLC and GM-CSF

## Key facts

- **NCT ID:** NCT02149225
- **Lead sponsor:** Immatics Biotechnologies GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10
- **Primary completion:** 2018-06
- **Final completion:** 2018-06
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2018-08-07

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02149225

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02149225, "GAPVAC Phase I Trial in Newly Diagnosed Glioblastoma Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02149225. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*